Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer

NCT00589186 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

BIOLOGICAL: Ad5F35-LMP1/LMP2-transduced autologous dendritic cells
DRUG: celecoxib
OTHER: flow cytometry
OTHER: immunoenzyme technique
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Centre, Singapore